Cargando…

Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome

BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor activation delays the progression of diabetic nephropathy (DN) in rodents. The NOD-like receptor 3 (Nlrp3) inflammasome plays an important role in DN. Dipeptidyl peptidase-4 inhibitors (DPP4I) inhibit the degradation of endogenous GLP-1 and variou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Birnbaum, Yochai, Bajaj, Mandeep, Qian, Jinqiao, Ye, Yumei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985834/ https://www.ncbi.nlm.nih.gov/pubmed/27547413 http://dx.doi.org/10.1136/bmjdrc-2016-000227

Ejemplares similares

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog
por: Edgerton, Dale S., et al.
Publicado: (2009)

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
por: Dave, Darshan J.
Publicado: (2011)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
por: Chen, Lin, et al.
Publicado: (2020)

Chalcone Derivatives From Abelmoschus manihot Seeds Restrain NLRP3 Inflammasome Assembly by Inhibiting ASC Oligomerization
por: Su, Jinsong, et al.
Publicado: (2022)

Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia
por: Chen, Yan, et al.
Publicado: (2017)

Prion Pathogenesis in the Absence of NLRP3/ASC Inflammasomes
por: Nuvolone, Mario, et al.
Publicado: (2015)

The Inflammasome Signaling Proteins ASC and IL-18 as Biomarkers of Psoriasis
por: Forouzandeh, Mahtab, et al.
Publicado: (2020)

ASC deglutathionylation is a checkpoint for NLRP3 inflammasome activation
por: Li, Shuhang, et al.
Publicado: (2021)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
por: Poncina, Nicol, et al.
Publicado: (2014)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms
por: Yang, Yinqiu, et al.
Publicado: (2017)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
por: Seong, Jong-Mi, et al.
Publicado: (2021)

CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors
por: Sato, K, et al.
Publicado: (2003)

Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G(2)/M arrest induced by topoisomerase II inhibitors
por: Aytac, U, et al.
Publicado: (2003)

The ASC Speck and NLRP3 Inflammasome Function Are Spatially and Temporally Distinct
por: Nagar, Abhinit, et al.
Publicado: (2021)

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Esaki, Hiroki, et al.
Publicado: (2017)

Dipeptidyl peptidase 4 expression is not associated with an activated fibroblast phenotype in idiopathic pulmonary fibrosis
por: Kadefors, Måns, et al.
Publicado: (2022)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Soluble Dipeptidyl Peptidase-4 Induces Fibroblast Activation Through Proteinase-Activated Receptor-2
por: Lee, Shih-Yi, et al.
Publicado: (2020)

Neurodegenerative Disease and the NLRP3 Inflammasome
por: Holbrook, Jonathan A., et al.
Publicado: (2021)

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
por: Frederich, Robert, et al.
Publicado: (2012)

Tyrosine Dephosphorylation of ASC Modulates the Activation of the NLRP3 and AIM2 Inflammasomes
por: Mambwe, Bezaleel, et al.
Publicado: (2019)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Tanshinone I specifically suppresses NLRP3 inflammasome activation by disrupting the association of NLRP3 and ASC
por: Zhao, Jia, et al.
Publicado: (2023)

Pyk2 activates the NLRP3 inflammasome by directly phosphorylating ASC and contributes to inflammasome-dependent peritonitis
por: Chung, I-Che, et al.
Publicado: (2016)

Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
por: Trzaskalski, Natasha A, et al.
Publicado: (2020)

The role of NLRP3 inflammasome in hepatocellular carcinoma
por: Zhao, Huijie, et al.
Publicado: (2023)

Adenovirus VA RNAI Blocks ASC Oligomerization and Inhibits NLRP3 Inflammasome Activation
por: Darweesh, Mahmoud, et al.
Publicado: (2019)

What are NLRP3-ASC specks? an experimental progress of 22 years of inflammasome research
por: Nagar, Abhinit, et al.
Publicado: (2023)

The deubiquitinating enzyme, ubiquitin‐specific peptidase 50, regulates inflammasome activation by targeting the ASC adaptor protein
por: Lee, Jae Young, et al.
Publicado: (2017)

Teuvincenone F Suppresses LPS-Induced Inflammation and NLRP3 Inflammasome Activation by Attenuating NEMO Ubiquitination
por: Zhao, Xibao, et al.
Publicado: (2017)

Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study
por: Shima, Kosuke Robert, et al.
Publicado: (2018)

NLRP3 inflammasome and its inhibitors: a review
por: Shao, Bo-Zong, et al.
Publicado: (2015)

Activation of Platelet NLRP3 Inflammasome in Crohn’s Disease
por: Zhang, Ge, et al.
Publicado: (2021)

Dipyridamole with Low-Dose Aspirin Augments the Infarct Size-Limiting Effects of Simvastatin
por: Ye, Yumei, et al.
Publicado: (2011)

Plant-derived bioactive compounds regulate the NLRP3 inflammasome to treat NAFLD
por: Huang, Qian, et al.
Publicado: (2022)

Artemisia Extract Suppresses NLRP3 and AIM2 Inflammasome Activation by Inhibition of ASC Phosphorylation
por: Kwak, Su-Bin, et al.
Publicado: (2018)

Ethanol extract of Chrysanthemum zawadskii inhibits the NLRP3 inflammasome by suppressing ASC oligomerization in macrophages
por: Jang, Ah-Ra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a84ougjjmpb3gpdi871cphg05m